Global progress towards the World Health Organization's (WHO) 2030 hepatitis C virus (HCV) elimination targets has stalled. Only 13 countries are on track to achieve either relative (80% reduction in new acquisitions, 65% in deaths) or absolute (<5 new acquisitions/100,000, <2 deaths/100,000) targets, with only two of the 20 highest-burden countries among them (China and Egypt) [1]. In 2024, 0.9 million people newly acquired HCV, a decline of only 8% from 2015; including nearly 10% of people who inject drugs (PWID) [2]. That year, the number of new acquisitions was about the same as the number cured [1]. Deaths from HCV-related cirrhosis and cancer remained high at 240,000, a reduction of a disappointing 12% from 2015 [2].
